Teligent News Releases http://investors.teligent.com/ Teligent News Releases en Teligent, Inc. Announces FDA Approval of Fluocinonide Ointment USP, 0.05% http://investors.teligent.com/news-releases/news-release-details/teligent-inc-announces-fda-approval-fluocinonide-ointment-usp BUENA, N.J., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Tue, 02 Oct 2018 09:00:00 -0400 Teligent News Releases 11341 Teligent Secures Critical Supply during Canadian National Drug Crisis despite Worldwide Shortage http://investors.teligent.com/news-releases/news-release-details/teligent-secures-critical-supply-during-canadian-national-drug TORONTO , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Teligent , Inc. (NASDAQ:TLGT) (“Teligent”), a specialty generic pharmaceutical company, averted a national sterile water and sodium chloride crisis by securing inventory to cover 100% of the Canadian Market following a breakdown in the global supply Thu, 16 Aug 2018 16:30:00 -0400 Teligent News Releases 11331 Teligent, Inc. Announces Second Quarter 2018 Results http://investors.teligent.com/news-releases/news-release-details/teligent-inc-announces-second-quarter-2018-results BUENA, N.J. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2018 . Second Quarter 2018 Highlights The Company adopted ASC 606: Revenue from Wed, 08 Aug 2018 16:15:00 -0400 Teligent News Releases 11306 Teligent, Inc. to Hold Conference Call for Second Quarter 2018 Results http://investors.teligent.com/news-releases/news-release-details/teligent-inc-hold-conference-call-second-quarter-2018-results BUENA, N.J. , Aug. 03, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Wednesday August 8, 2018 to discuss the 2 nd quarter 2018 financial results and business Fri, 03 Aug 2018 08:30:00 -0400 Teligent News Releases 11301 Teligent, Inc. Announces FDA Approval of Hydrocortisone Lotion USP, 2.5% http://investors.teligent.com/news-releases/news-release-details/teligent-inc-announces-fda-approval-hydrocortisone-lotion-usp-25 BUENA, N.J. , July 30, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Mon, 30 Jul 2018 08:30:00 -0400 Teligent News Releases 11291 Teligent, Inc. Announces FDA Approval of Hydrocortisone Cream USP, 2.5% http://investors.teligent.com/news-releases/news-release-details/teligent-inc-announces-fda-approval-hydrocortisone-cream-usp-25 BUENA, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Tue, 24 Jul 2018 15:03:00 -0400 Teligent News Releases 11286 Teligent, Inc. Announces FDA Approval of Lidocaine and Prilocaine Cream USP, 2.5%/2.5% http://investors.teligent.com/news-releases/news-release-details/teligent-inc-announces-fda-approval-lidocaine-and-prilocaine BUENA, N.J. , July 02, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Mon, 02 Jul 2018 08:00:00 -0400 Teligent News Releases 11281 Teligent, Inc. Announces FDA Approval of Fluocinonide Gel, 0.05% http://investors.teligent.com/news-releases/news-release-details/teligent-inc-announces-fda-approval-fluocinonide-gel-005 BUENA, N.J. , June 20, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Wed, 20 Jun 2018 09:22:00 -0400 Teligent News Releases 11271 Teligent, Inc. Announces FDA Approval of Diflorasone Diacetate Ointment 0.05% http://investors.teligent.com/news-releases/news-release-details/teligent-inc-announces-fda-approval-diflorasone-diacetate BUENA, N.J. , June 13, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Wed, 13 Jun 2018 16:40:00 -0400 Teligent News Releases 11266 Teligent, Inc. Announces Closing Of $25 Million Secured Credit Facility http://investors.teligent.com/news-releases/news-release-details/teligent-inc-announces-closing-25-million-secured-credit BUENA, N.J. , June 05, 2018 (GLOBE NEWSWIRE) -- TELIGENT, Inc. (NASDAQ:TLGT) Teligent, Inc. (“Teligent”) announced today that it has entered into a Credit Agreement with certain funds managed by Highbridge Capital Management, LLC , an existing stakeholder, on June 1 , 2018.  Pursuant to the Credit Tue, 05 Jun 2018 16:45:00 -0400 Teligent News Releases 11256